SCHEDULE 13G/A: Conestoga Capital Advisors and Funds Disclose Significant Stake in Mesa Laboratories
Beneficial Ownership Disclosure
Conestoga Capital Advisors and its affiliated funds have filed an updated Schedule 13G, revealing beneficial ownership of 11.38% and 7.62% respectively, in Mesa Laboratories Inc.'s common stock as of December 31, 2024.
Summary
- Conestoga Capital Advisors reported beneficial ownership of 618,111 shares of Mesa Laboratories Inc. common stock, representing 11.38% of the class.
- Conestoga Capital Advisors holds sole voting power over 573,037 shares and sole dispositive power over 618,111 shares.
- CONESTOGA FUNDS reported beneficial ownership of 413,984 shares of Mesa Laboratories Inc. common stock, representing 7.62% of the class.
- CONESTOGA FUNDS holds sole voting power over 413,985 shares and sole dispositive power over 413,985 shares.
- Both Conestoga Capital Advisors and CONESTOGA FUNDS are Delaware entities, with their principal business office located in Wayne, Pennsylvania.
- The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of Mesa Laboratories Inc.
Sentiment
Score: 5
Explanation: The document is a factual disclosure of beneficial ownership, which is neutral in sentiment. It does not contain positive or negative operational or financial news.
Future Outlook
NA
Industry Context
This filing is a routine disclosure of institutional ownership, common in the financial industry for investment advisors and funds managing significant stakes in publicly traded companies. It reflects a passive investment position rather than an active strategic move within the industry.
Stakeholder Impact
- Shareholders: Provides transparency regarding significant institutional holdings, which can influence market perception and liquidity.
Key Dates
| Date | Description |
|---|---|
| 12/31/2024 | Date of event which requires filing of this statement (reporting period end date) |
| 01/09/2025 | Signature date of the Schedule 13G filing |
Keywords
Mesa Laboratories Inc, Conestoga Capital Advisors, CONESTOGA FUNDS, Schedule 13G, Beneficial Ownership, Institutional Ownership, SEC Filing, Common Stock, Investment Adviser, Investment Company
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.